Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eunyoung Suh

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Child Health Nursing Research|July 31, 2024
What makes a good reviewer?Eunyoung Suh
JMIR Cancer|June 21, 2026
Multi-Turn LLM-Based Conversational Agents for Patients with Cancer and Caregivers: A Scoping ReviewYeongrok Jeong, Hyejeon Cha, Eunyoung Suh
Journal of the American Heart Association|November 10, 2021
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINERGary E Raskob, Alex C Spyropoulos, Theodore E Spiro, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 21, 2019
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN StudyAlex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, et al.
American Heart Journal|February 12, 2021
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD studyWarren H Capell, Elliot S Barnathan, Gregory Piazza, et al.
Journal of Korean Academy of Nursing|June 16, 2012
[Analysis of trends and contents of nursing doctoral dissertations in Korea]Kwang-Ja Lee, Younhee Kang, Mee Ock Gu, et al.
Clinical Pharmacology and Therapeutics|August 22, 2025
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial FibrillationWangda Zhou, Emily Bozenhardt, Gregory E Alexander, et al.
Thrombosis and Haemostasis|January 25, 2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER TrialsJeffrey I Weitz, Gary E Raskob, Alex C Spyropoulos, et al.
The New England Journal of Medicine|August 28, 2018
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical IllnessAlex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
Journal of Thrombosis and Haemostasis : JTH|July 27, 2021
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or olderWalter Ageno, Renato D Lopes, Mark Goldin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Child Health Nursing Research|July 31, 2024
What makes a good reviewer?Eunyoung Suh
JMIR Cancer|June 21, 2026
Multi-Turn LLM-Based Conversational Agents for Patients with Cancer and Caregivers: A Scoping ReviewYeongrok Jeong, Hyejeon Cha, Eunyoung Suh
Journal of the American Heart Association|November 10, 2021
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINERGary E Raskob, Alex C Spyropoulos, Theodore E Spiro, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 21, 2019
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN StudyAlex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, et al.
American Heart Journal|February 12, 2021
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD studyWarren H Capell, Elliot S Barnathan, Gregory Piazza, et al.
Journal of Korean Academy of Nursing|June 16, 2012
[Analysis of trends and contents of nursing doctoral dissertations in Korea]Kwang-Ja Lee, Younhee Kang, Mee Ock Gu, et al.
Clinical Pharmacology and Therapeutics|August 22, 2025
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial FibrillationWangda Zhou, Emily Bozenhardt, Gregory E Alexander, et al.
Thrombosis and Haemostasis|January 25, 2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER TrialsJeffrey I Weitz, Gary E Raskob, Alex C Spyropoulos, et al.
The New England Journal of Medicine|August 28, 2018
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical IllnessAlex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
Journal of Thrombosis and Haemostasis : JTH|July 27, 2021
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or olderWalter Ageno, Renato D Lopes, Mark Goldin, et al.
Pageof 1